Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Rabitsch

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Bone Marrow Transplantation|December 18, 2012
In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burdenN Blijlevens, M de Château, G Krivan, et al.
Annals of Hematology|August 25, 1999
Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantationF Keil, P Kalhs, X Chen, et al.
European Journal of Clinical Investigation|August 31, 2007
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapyK J Aichberger, S Herndlhofer, H Agis, et al.
Acta Oncologica (Stockholm, Sweden)|February 7, 2001
Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patientsH T Greinix, W Linkesch, M Seifert, et al.
Bone Marrow Transplantation|September 9, 2008
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCTS McCann, M Schwenkglenks, P Bacon, et al.
Journal of Cancer Research and Clinical Oncology|February 28, 2016
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysisW Rabitsch, M Bojic, P Wohlfarth, et al.
Bone Marrow Transplantation|January 23, 1999
Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemiaE Reiter, H T Greinix, S Brugger, et al.
Transfusion|February 13, 2001
PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCRF Keil, G Mitterbauer, X Chen, et al.
Bone Marrow Transplantation|May 7, 1999
Low transplant-related mortality in patients receiving unrelated donor marrow grafts for leukemiaP Kalhs, S Brugger, E Reiter, et al.
Leukemia|March 10, 2001
Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplantsF Keil, E Prinz, P Kalhs, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Bone Marrow Transplantation|December 18, 2012
In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burdenN Blijlevens, M de Château, G Krivan, et al.
Annals of Hematology|August 25, 1999
Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantationF Keil, P Kalhs, X Chen, et al.
European Journal of Clinical Investigation|August 31, 2007
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapyK J Aichberger, S Herndlhofer, H Agis, et al.
Acta Oncologica (Stockholm, Sweden)|February 7, 2001
Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patientsH T Greinix, W Linkesch, M Seifert, et al.
Bone Marrow Transplantation|September 9, 2008
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCTS McCann, M Schwenkglenks, P Bacon, et al.
Journal of Cancer Research and Clinical Oncology|February 28, 2016
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysisW Rabitsch, M Bojic, P Wohlfarth, et al.
Bone Marrow Transplantation|January 23, 1999
Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemiaE Reiter, H T Greinix, S Brugger, et al.
Transfusion|February 13, 2001
PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCRF Keil, G Mitterbauer, X Chen, et al.
Bone Marrow Transplantation|May 7, 1999
Low transplant-related mortality in patients receiving unrelated donor marrow grafts for leukemiaP Kalhs, S Brugger, E Reiter, et al.
Leukemia|March 10, 2001
Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplantsF Keil, E Prinz, P Kalhs, et al.
Pageof 5